Stockscreener 앱 받기
2.11%
Amgen Inc 주식(AMGN)의 최신 뉴스
AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’ - Stocktwits
How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story - simplywall.st
Amgen’s Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal - Yahoo Finance
Amgen (AMGN) Rises Higher Than Market: Key Facts - Yahoo Finance
Obesity Drug Sector Evolves as Amgen (AMGN) Advances Pipeline Am - GuruFocus
Mesirow buys Amgen’s Deerfield campus in $151 million sale-leaseback - Crain's Chicago Business
Amgen stock last at USD 410.86, up 1.19 percent in New York trading - AD HOC NEWS
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
Amgen stock trades at USD 406.04 after pipeline win - AD HOC NEWS
Amgen Inc. $AMGN Stock Purchased by Envestnet Portfolio Solutions Inc. - MarketBeat
Amgen stock heads into the open after a 0.01 percent loss - AD HOC NEWS
Amgen Inc. (AMGN34.SA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amgen Gains as Sjögren's Drug Clears Phase 3 - GuruFocus
Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
Amgen (AMGN) Stock Could Be 40% Undervalued On Phase 3 Sjögren’s Data - simplywall.st
Amgen reports positive topline Phase 3 Sjögren’s results - European Pharmaceutical Review
Amgen stock heads into the open after a 4.34 percent gain - AD HOC NEWS
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease - Yahoo! Finance Canada
QRG Capital Management Inc. Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Envestnet Asset Management Inc. Acquires 326,260 Shares of Amgen Inc. $AMGN - MarketBeat
When Colorectal Cancer Strikes Early - Amgen
Amgen stock was last quoted after the close - AD HOC NEWS
Amgen price target raised by Jefferies to $410 after positive Sjögren's data - Yahoo Finance
Amgen says dazodalibep met Phase 3 Sjögren's endpoint - Mugglehead Investment Magazine
Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build - TradingKey
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study - Yahoo Finance
Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating - marketscreener.com
Amgen Stock Gains After Announcing Positive Phase 3 Sjögren’s Disease Trial Results - TIKR.com
Canaccord reiterates Amgen stock Hold rating on pipeline win By Investing.com - Investing.com Canada
Amgen stock rises 4.34 percent as trial data lift pipeline hopes - AD HOC NEWS
Oppenheimer reiterates Amgen stock rating on positive trial data - Investing.com India
Jefferies raises Amgen stock price target on drug trial success - Investing.com India
Amgen (AMGN) Following Its Sjögren's Trial Win Through A Valuation Lens - simplywall.st
Amgen touts Phase III success in systemic Sjögren's disease - The Pharma Letter
What is changing in the investment case for Amgen (NASDAQ:AMGN)? - Kalkine Media
Ionis, Otsuka's Phase 3 win in ALS subtype; Boehringer's up to $1B cancer deal - Endpoints News
Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Is Amgen Inc (AMGN) Overvalued After 4.3% Rally? GF Value Says O - GuruFocus
Amgen's autoimmune drug succeeds in late-stage trial - Reuters
Amgen stock surges on positive Sjögren’s trial results - Investing.com
Amgen Inc.’s Stock Price Soars to $410.24, Marking a Robust 4.34% Increase - Smartkarma
Amgen stock ends the day 3.36 percent higher at USD 406.37 - AD HOC NEWS
Amgen’s Dazodalibep Outlook Is Brighter After First Phase III Readout - insights.citeline.com
Amgen, Vicor among market cap stock movers on Tuesday - Investing.com India
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds - MedCity News
Amgen, Vicor among market cap stock movers on Tuesday By Investing.com - Investing.com Australia
Amgen’s autoimmune drug succeeds in late-stage trial - WTVB
Amgen reports a Phase 3 win with Sjögren’s drug candidate - BioPharma Dive
Amgen Ranks #4 on Forbes’ Most Innovative Large Companies List - Amgen
Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data - Benzinga
State Street Corp Increases Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Posted Positive Phase 3 Results In Sjögren's Disease - Yahoo Finance
Why Amgen (AMGN) Stock Is Up Today - Quiver Quantitative
Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement - TradingKey
Amgen Drug May Offer Sjögren’s Patients First Effective Therapy - Bloomberg
Why is Amgen stock surging today? - Investing.com
Amgen posts trial win for Sjögren's disease drug (AMGN:NASDAQ) - Seeking Alpha
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE - Amgen
1.23%
자본화:
|
볼륨(24시간):